What do experts recommend for TMS depression treatment?
A panel of 18 expert clinicians and researchers has published an updated consensus statement on transcranial magnetic stimulation for depression, replacing the 2018 guidance and concluding that TMS continues to show broad evidence for safety and efficacy. This is a consensus document and narrative review, not a new clinical trial: the group reviewed the published literature and voted on recommendations rather than treating patients themselves.
The statement comes from the National Network of Depression Centers neuromodulation task group, which met monthly by video conference between October 2022 and April 2024. The drafted document was submitted to the executive committees of the International Federation of Clinical Neurophysiology and the Clinical TMS Society for review and endorsement.
What the data show:
- Scope of the review: 4,238 abstracts screened, 2,396 unique articles met inclusion criteria across MEDLINE/PubMed, Cochrane, PsycINFO and Embase
- Efficacy in major depression: A meta-analysis of 65 randomized trials, 2,982 participants, found a large antidepressant effect with high frequency rTMS to the left dorsolateral prefrontal cortex
- Odds of responding: Active treatment carried roughly 138% higher odds of response and 145% higher odds of remission than sham
- Newer protocols: Newer forms of TMS are faster and potentially more effective than conventional repetitive TMS
- Expanding label: The FDA has extended the label for one TMS device and protocol down to age 15
Dr. Kumar’s Take
The part of this consensus I find most clinically useful is the suggestion that TMS deserves consideration earlier in the treatment algorithm rather than only after a long series of failed medications. Two recent studies support that: in one, adding rTMS beat switching medications in patients who had already failed two or more drugs, and in another, patients randomized to rTMS had greater reductions in depressive symptoms, particularly anhedonia and anxiety, than patients randomized to a medication switch or augmentation. When a treatment with this safety record performs that well against a drug change, waiting through several more failed prescriptions is hard to justify. The other point worth sitting with is that durability is the weaker part of the evidence base. Acute response is well established. Keeping people well afterward is still being worked out.
Guideline at a Glance
The task group used a modified Delphi method to reach consensus: blinded voting followed by anonymized written justifications circulated back to the group, repeated until majority consensus was reached. All members then had the opportunity to edit the drafted statement.
The literature search covered September 1, 2016, the end date of the previous review, through September 12, 2022, with additional articles added by expert recommendation up to October 1, 2024. Search terms covered transcranial magnetic stimulation and seven related MeSH terms, alongside major depressive disorder, treatment-resistant depression, postpartum depression, dysthymic disorder, premenstrual dysphoric disorder, vascular depression, bipolar depression and 33 further terms.
Beyond efficacy and safety, the document addresses provider training, roles and responsibilities, and documentation standards for TMS practice in the United States.
Results in Real Numbers
The acute antidepressant effect of left dorsolateral prefrontal cortex rTMS rests on three pivotal randomized controlled trials, a large multisite non-inferiority study comparing intermittent theta burst stimulation against 10 Hz rTMS, and numerous meta-analyses. One meta-analysis pooling 65 randomized trials and 2,982 participants found a large effect size for high frequency rTMS to the left dorsolateral prefrontal cortex, Hedge’s g of 0.79, 95% confidence interval 0.61 to 0.98. In that same analysis, active treatment carried about 138% higher odds of response and about 145% higher odds of remission compared with sham.
Outside the trial setting, one large retrospective study of 5,010 real-world patients receiving rTMS for depression reported response rates of 58% to 83% and remission rates of 28% to 62%, depending on whether the outcome came from a self-report or a clinician-administered scale.
The evidence is not uniformly positive. One large clinical trial of 164 patients in the VA health system failed to show that active TMS beat sham, attributed in part to a high sham response rate.
On durability, a systematic review and meta-analysis of 18 studies found sustained response rates of 66.5% at 3 months, 52.9% at 6 months, and 46.3% at 12 months after treatment. That analysis included 11 studies in which participants received maintenance rTMS, which is not widely available in the United States. Maintenance mattered: 6-month sustained response was 61.1% in studies using a maintenance protocol against 38.5% in studies without one. Female sex also predicted greater durability.
Who Benefits Most
TMS was cleared by the FDA in 2008 for major depressive disorder in adults, and multiple systems have since received 510(k) clearances. The strongest and most reproduced evidence remains high frequency rTMS to the left dorsolateral prefrontal cortex for major depressive disorder.
For depression with comorbid anxiety, the FDA cleared the H1 coil in 2021 based on retrospective analysis of anxiety symptoms measured during three randomized trials totaling 442 patients, which found a modest effect favoring active treatment, sustained at 16 weeks. Clearance for that indication later followed for some figure-8 coil manufacturers.
Depression comorbid with Parkinson’s disease has been a focus of recent research, with several meta-analyses finding moderate effects, primarily with high frequency left dorsolateral prefrontal cortex rTMS. Post-stroke depression has accumulating evidence: seven meta-analyses published in the past six years, five of them with more than 1,000 participants, suggest a strong antidepressant effect of high frequency left dorsolateral prefrontal cortex rTMS, and in several cases low frequency right dorsolateral prefrontal cortex rTMS, with consistently large effect sizes.
Bipolar depression is less settled. The largest of three recent meta-analyses pooled 11 studies and 345 adults across depressive, mixed and manic episodes, and found a small but significant improvement in depressive symptoms, with a number needed to treat of 10 for remission. Other studies have produced mixed and inconclusive results. Evidence for treating manic symptoms is weaker still.
Safety, Limits, and Caveats
Across 135 participants with bipolar depression treated alongside mood stabilizers or antipsychotics, one case of treatment-emergent mania was reported, occurring with left-sided high frequency stimulation. Separate work has raised concern about higher rates of treatment-emergent mania with intermittent theta burst stimulation, along with unclear efficacy in that population.
The treatment itself involves repeated, noninvasive, targeted stimulation of the prefrontal cortex delivered over several days. Newer protocols, including intermittent theta burst stimulation, were developed to shorten total stimulation and treatment time, and accelerated protocols are pushing the boundaries of total pulses delivered and time to response.
Two limits on the review itself are worth naming. The volume of literature, 2,396 articles, was beyond the scope of a formal systematic review, so topic leaders selected the references they considered relevant. References of included studies were not systematically searched for further eligible studies. The group encourages further exploration of targeting methods, use in special populations, and accelerated protocols.
Practical Takeaways
- Consider rTMS earlier in the treatment sequence for treatment-resistant depression rather than only after many medication trials
- High frequency stimulation of the left dorsolateral prefrontal cortex has the deepest evidence base for major depressive disorder
- Ask about maintenance planning, since sustained response at 6 months was substantially higher in studies that used a maintenance protocol
- Newer theta burst and accelerated protocols cut treatment time and may prove more effective, though optimal parameters are still under study
- In bipolar depression, weigh the effect size against reported treatment-emergent mania, particularly with theta burst protocols
- Provider training, defined roles, and documentation are addressed directly in the consensus and should be part of any TMS program
Related Studies and Research
Episode 31: Depression Explained, The Biology Behind the Darkness
Episode 32: Depression Recovery Roadmap: A Step-by-Step, Evidence-Based Plan
Stanford Accelerated Intelligent Neuromodulation Therapy for Treatment-Resistant Depression
Accelerated TMS - moving quickly into the future of depression treatment
Default Mode Network Mechanisms of Transcranial Magnetic Stimulation in Depression
FAQs
When should TMS be considered for depression treatment?
Two recent studies cited in the consensus suggest rTMS deserves a place earlier in antidepressant treatment algorithms. In one, rTMS augmentation was superior to switching medications in patients who had failed two or more drugs. In the other, patients with treatment-resistant depression randomized to rTMS had greater reductions in depressive symptoms, specifically anhedonia and anxiety, than those randomized to a medication switch or pharmacologic augmentation.
What makes this consensus different from previous guidelines?
It updates the 2018 statement from the National Network of Depression Centers and the American Psychiatric Association Council on Research task force, incorporating research published since September 2016. The drafted document was also submitted to the International Federation of Clinical Neurophysiology and the Clinical TMS Society for review and endorsement.
Does TMS keep working after the treatment course ends?
Durability is less well characterized than acute response. A meta-analysis of 18 studies found sustained response in 66.5% of patients at 3 months, 52.9% at 6 months, and 46.3% at 12 months. Studies that included a maintenance protocol reported 61.1% sustained response at 6 months, against 38.5% in studies without one.
Can adolescents receive TMS?
The FDA has extended the label for one specific TMS device and protocol down to age 15.
Bottom Line
This updated consensus from an 18-member expert task group, drawn from a screen of 4,238 abstracts and review of 2,396 articles, concludes that TMS continues to demonstrate broad evidence for safety and efficacy in depression. The strongest signal is for high frequency stimulation of the left dorsolateral prefrontal cortex in major depressive disorder, where a 65-trial meta-analysis found a large effect and roughly 138% higher odds of response than sham. Newer, faster protocols look promising, and the open questions now are targeting, special populations, and how best to sustain the benefit.
